Overview

Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism. The main objective of this study is to demonstrate the efficacy of paricalcitol injection in reducing levels of parathyroid hormone without clinically significant hypercalcemia, compared to maxacalcitol injection.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Calcitriol
Ergocalciferols
Maxacalcitol